摘要
目的:探讨新型靶向治疗药物厄洛替尼对人卵巢癌细胞株SKOV3的作用。方法:体外培养人卵巢癌细胞株SKOV-3,采用MTT(噻唑蓝)检测不同浓度(0,10,15,20,40,50,60,70,80μmol/L)的厄洛替尼作用不同时间(24,48,72h)的细胞增殖活力变化,应用流式细胞仪对不同药物浓度作用后细胞凋亡、细胞周期情况进行分析。结果:厄洛替尼对人卵巢癌SKOV3细胞有抑制作用,且呈现时间及剂量依赖性。对照组与实验组比较,差异有统计学意义。随着药物浓度的增加,正常细胞逐渐减少,早期凋亡及晚期凋亡细胞呈现上升趋势,不同浓度组间比较有差异,差异有统计学意义。不同浓度的厄洛替尼作用于SKOV-3后,各浓度组相比较,随着药物浓度的增加,G0/G1期细胞数量明显增加,S期及G2/M期细胞数量呈减少趋势,差异有统计学意义。结论:厄洛替尼具有明显抑制卵巢癌细胞的增殖活力,促进细胞凋亡的作用,将SK0V3细胞周期阻滞于G0/G1期。其在卵巢癌的治疗中,可能具有一定的临床意义。
Objective To investigate the effection of new targeted therapy drugs erlotinib on human ovarian cancer cell line SKOV3 in vitro and to explore its influence on cell cycle. Methods Ovarian cancer cell line SKOV3 were cultured in vitro under the irritation of erlotinib with different concentrations( 0、10、15、20、40、50、60、70 and 80 μmol /L) for 24h、48h and 72 h. The inhibition rates were detected by MTT array; The cell cycle and Apoptosis of SKOV3 cells exposed to erlotinib with different concentrations were analyzed by flow cytometry. Results Erlotinib obviously inhibited the proliferation of SKOV3 cells in a time and dose dependent manner,which had the significant differences compared with the control groups( P < 0. 05). With the increasing of drug concentration the normal cells gradually decreased,while early apoptotic cells and late apoptotic cells were in an upward trend,There were significant differences between different concentrations comparison groups,After influenced by different concentration of erlotinib,With the increasing of drug concentration the numbers of the G0 /G1 phase of SKOV-3cells were improved significanty while the numbers of S phase and G2 /M phase were decreased. The differences were statistically significant comparing the groups. Conclusion Erlotinib can obviously inhibit SKOV3 cell proliferation and induce cell apoptosis,by blocking SKOV3 in G0 /G1 in the cell cycle,It is may have some clinical significance in treatment of ovarian cancer.
出处
《晓庄学院学报（医学版）》
2014年第3期16-20,共5页
Journal of Hunan Normal University(Medical Sciences)
基金
湖南省科技厅科技计划(2012TT2022)
